Shots:

• The approval is based on P-II CheckMate -142 study evaluating Opdivo + Yervoy in patients with dMMR or MSI-H mCRC whose disease had progressed during or after prior treatment with CT
• Results: @ minimum follow-up of 46.9mos. improvement in ORR (64.7%) with 12.6% patients achieve a CR- m-DoR was not reached & safety profile was consistent with previous studies of combination in other tumor types
• The combination marks the 1st approved dual immunotherapy regimen for any GI tumor & also approved for NSCLC & RCC in the EU. The marketing authorization approve the use of combination in all EU member states- Norway- Iceland & Liechtenstein

  Ref: BMS | Image: BMS